Barclays’s Histogen Inc. Common Stock HSTO Stock Holding History

Barclays’s Portfolio HSTO Stock Details HSTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-59	Closed	-$20K	–	7462
2018 Q4	$20K	Buy	+59	New	+$45.8K	﹤0.01%	5907
2018 Q3	–	Sell	-269	Closed	-$230K	–	7526
2018 Q2	$230K	Buy	269 +242	+896%	+$201K	﹤0.01%	4597
2018 Q1	$32K	Buy	27 +6	+29%	+$6.63K	﹤0.01%	6211
2017 Q4	$19K	Sell	21 -67	-76%	-$61.9K	﹤0.01%	6320
2017 Q3	$97K	Buy	+88	New	+$100K	﹤0.01%	4965
2017 Q2	–	Hold	0	–	–	–	7059
2017 Q1	–	Sell	-22	Closed	-$23K	–	7082
2016 Q4	$23K	Buy	+22	New	+$9.98K	﹤0.01%	5566
2016 Q3	–	Hold	0	–	–	–	6883
2016 Q2	–	Hold	0	–	–	–	6743
2016 Q1	–	Hold	0	–	–	–	6545
2015 Q4	–	Hold	0	–	–	–	6776
2015 Q3	–	Hold	0	–	–	–	7153
2015 Q2	–	Sell	-16	Closed	-$18.8K	–	7287
2015 Q1	$22K	Buy	+16	New	+$20.3K	﹤0.01%	5782
2014 Q3	–	Sell	-6	Closed	-$11K	–	7882
2014 Q2	$11K	Buy	6 +5	+500%	+$6.68K	﹤0.01%	6797
2014 Q1	$2K	Hold	1	–	–	﹤0.01%	7418
2013 Q4	$1K	Sell	1 -1	-50%	-$1.6K	﹤0.01%	7462
2013 Q3	$3K	Buy	+2	New	+$3.72K	﹤0.01%	7131

Other funds holding HSTO

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Barclays's HSTO Position: Q1 2019 in Review

Barclays sold out of Histogen Inc. Common Stock (HSTO) in Q1 2019, closing a stake of 59 shares — an estimated $20K sold.

Barclays first reported a position in HSTO in Q3 2013 and held it in 11 quarters. The position peaked at $230K in Q2 2018. 42 funds tracked by Wall St. Rank hold HSTO as of Q1 2019.

Barclays reported no remaining Histogen Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Barclays sold 59 Histogen Inc. Common Stock shares in Q1 2019, an estimated $20K.
Barclays first reported a position in Histogen Inc. Common Stock in Q3 2013 and held it in 11 quarters.
Barclays's Histogen Inc. Common Stock position peaked at $230K in Q2 2018.
42 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q1 2019.

Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.